APO Research
Talk to an analyst

APO RESEARCH · REPORT

Homozygous Familial Hypercholesterolemia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Homozygous Familial Hypercholesterolemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025180 pages

Choose your research edition.

Industry ResearchHomozygous Familial Hypercholesterolemia Treatment Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Homozygous Familial Hypercholesterolemia Treatment Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Homozygous Familial Hypercholesterolemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Homozygous Familial Hypercholesterolemia Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Homozygous Familial Hypercholesterolemia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Homozygous Familial Hypercholesterolemia Treatment include The Medicines Company, RegenxBio Inc, Regeneron Pharmaceuticals Inc, LipimetiX Development Inc, Gemphire Therapeutics Inc, Daewoong Co Ltd and CymaBay Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Homozygous Familial Hypercholesterolemia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Homozygous Familial Hypercholesterolemia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Homozygous Familial Hypercholesterolemia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Homozygous Familial Hypercholesterolemia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Homozygous Familial Hypercholesterolemia Treatment Segment by Company

The Medicines Company

RegenxBio Inc

Regeneron Pharmaceuticals Inc

LipimetiX Development Inc

Gemphire Therapeutics Inc

Daewoong Co Ltd

CymaBay Therapeutics Inc

Homozygous Familial Hypercholesterolemia Treatment Segment by Type

Alirocumab

Evinacumab

AEM-2814

AEM-2802

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Application

Clinic

Hospital

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Homozygous Familial Hypercholesterolemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Homozygous Familial Hypercholesterolemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Homozygous Familial Hypercholesterolemia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Homozygous Familial Hypercholesterolemia Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Homozygous Familial Hypercholesterolemia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Homozygous Familial Hypercholesterolemia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Homozygous Familial Hypercholesterolemia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Homozygous Familial Hypercholesterolemia Treatment Industry Trends Table 2. Homozygous Familial Hypercholesterolemia Treatment Industry Drivers Table 3. Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges Table 4. Homozygous Familial Hypercholesterolemia Treatment Industry Restraints Table 5. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers, Product Type & Application Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Homozygous Familial Hypercholesterolemia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alirocumab Table 17. Major Manufacturers of Evinacumab Table 18. Major Manufacturers of AEM-2814 Table 19. Major Manufacturers of AEM-2802 Table 20. Major Manufacturers of Others Table 21. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2026) & (k units) Table 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2027-2032) & (k units) Table 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2026) Table 25. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2027-2032) Table 26. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2026) & (k units) Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2027-2032) & (k units) Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2026) & (k units) Table 36. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2027-2032) & (k units) Table 37. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2026) Table 38. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2027-2032) Table 39. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2026) & (k units) Table 41. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2027-2032) & (k units) Table 42. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2026) Table 43. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2027-2032) Table 44. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026) & (k units) Table 46. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2026) Table 47. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 51. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 52. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 54. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 61. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2026) Table 65. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2027-2032) Table 66. The Medicines Company Company Information Table 67. The Medicines Company Business Overview Table 68. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 70. The Medicines Company Recent Development Table 71. RegenxBio Inc Company Information Table 72. RegenxBio Inc Business Overview Table 73. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 75. RegenxBio Inc Recent Development Table 76. Regeneron Pharmaceuticals Inc Company Information Table 77. Regeneron Pharmaceuticals Inc Business Overview Table 78. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 80. Regeneron Pharmaceuticals Inc Recent Development Table 81. LipimetiX Development Inc Company Information Table 82. LipimetiX Development Inc Business Overview Table 83. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 85. LipimetiX Development Inc Recent Development Table 86. Gemphire Therapeutics Inc Company Information Table 87. Gemphire Therapeutics Inc Business Overview Table 88. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 90. Gemphire Therapeutics Inc Recent Development Table 91. Daewoong Co Ltd Company Information Table 92. Daewoong Co Ltd Business Overview Table 93. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 95. Daewoong Co Ltd Recent Development Table 96. CymaBay Therapeutics Inc Company Information Table 97. CymaBay Therapeutics Inc Business Overview Table 98. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 100. CymaBay Therapeutics Inc Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Homozygous Familial Hypercholesterolemia Treatment Distributors List Table 104. Homozygous Familial Hypercholesterolemia Treatment Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Homozygous Familial Hypercholesterolemia Treatment Product Image Figure 2. Global Homozygous Familial Hypercholesterolemia Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Homozygous Familial Hypercholesterolemia Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Homozygous Familial Hypercholesterolemia Treatment Sales (2021-2032) & (k units) Figure 5. Global Homozygous Familial Hypercholesterolemia Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Homozygous Familial Hypercholesterolemia Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alirocumab Image Figure 9. Evinacumab Image Figure 10. AEM-2814 Image Figure 11. AEM-2802 Image Figure 12. Others Image Figure 13. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032) Figure 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032) Figure 25. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032) Figure 28. North America Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 30. U.S. Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 35. Germany Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 42. China Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2032) Figure 50. Brazil Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Homozygous Familial Hypercholesterolemia Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Homozygous Familial Hypercholesterolemia Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Figure 61. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Homozygous Familial Hypercholesterolemia Treatment Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Alirocumab
  • Evinacumab
  • AEM-2814
  • AEM-2802
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • The Medicines Company
  • RegenxBio Inc
  • Regeneron Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Gemphire Therapeutics Inc
  • Daewoong Co Ltd
  • CymaBay Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Homozygous Familial Hypercholesterolemia Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Homozygous Familial Hypercholesterolemia Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Homozygous Familial Hypercholesterolemia Treatment Market Dynamics
  1. 2.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
  2. 2.2 Homozygous Familial Hypercholesterolemia Treatment Industry Drivers
  3. 2.3 Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges
  4. 2.4 Homozygous Familial Hypercholesterolemia Treatment Industry Restraints
3 Homozygous Familial Hypercholesterolemia Treatment Market by Manufacturers
  1. 3.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Homozygous Familial Hypercholesterolemia Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Homozygous Familial Hypercholesterolemia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Homozygous Familial Hypercholesterolemia Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Homozygous Familial Hypercholesterolemia Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Homozygous Familial Hypercholesterolemia Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Homozygous Familial Hypercholesterolemia Treatment Tier 1, Tier 2, and Tier 3
4 Homozygous Familial Hypercholesterolemia Treatment Market by Type
  1. 4.1 Homozygous Familial Hypercholesterolemia Treatment Type Introduction
  2. 4.1.1 Alirocumab
  3. 4.1.2 Evinacumab
  4. 4.1.3 AEM-2814
  5. 4.1.4 AEM-2802
  6. 4.1.5 Others
  7. 4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type
  8. 4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2021-2032)
  10. 4.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2021-2032)
  11. 4.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type
  12. 4.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2021-2032)
  14. 4.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2021-2032)
5 Homozygous Familial Hypercholesterolemia Treatment Market by Application
  1. 5.1 Homozygous Familial Hypercholesterolemia Treatment Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application
  6. 5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application
  10. 5.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2021-2032)
6 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region
  1. 6.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
  1. 7.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
  2. 7.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032)
  8. 7.2.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 The Medicines Company
  2. 8.1.1 The Medicines Company Company Information
  3. 8.1.2 The Medicines Company Business Overview
  4. 8.1.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  6. 8.1.5 The Medicines Company Recent Developments
  7. 8.2 RegenxBio Inc
  8. 8.2.1 RegenxBio Inc Company Information
  9. 8.2.2 RegenxBio Inc Business Overview
  10. 8.2.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  12. 8.2.5 RegenxBio Inc Recent Developments
  13. 8.3 Regeneron Pharmaceuticals Inc
  14. 8.3.1 Regeneron Pharmaceuticals Inc Company Information
  15. 8.3.2 Regeneron Pharmaceuticals Inc Business Overview
  16. 8.3.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  18. 8.3.5 Regeneron Pharmaceuticals Inc Recent Developments
  19. 8.4 LipimetiX Development Inc
  20. 8.4.1 LipimetiX Development Inc Company Information
  21. 8.4.2 LipimetiX Development Inc Business Overview
  22. 8.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  24. 8.4.5 LipimetiX Development Inc Recent Developments
  25. 8.5 Gemphire Therapeutics Inc
  26. 8.5.1 Gemphire Therapeutics Inc Company Information
  27. 8.5.2 Gemphire Therapeutics Inc Business Overview
  28. 8.5.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  30. 8.5.5 Gemphire Therapeutics Inc Recent Developments
  31. 8.6 Daewoong Co Ltd
  32. 8.6.1 Daewoong Co Ltd Company Information
  33. 8.6.2 Daewoong Co Ltd Business Overview
  34. 8.6.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  36. 8.6.5 Daewoong Co Ltd Recent Developments
  37. 8.7 CymaBay Therapeutics Inc
  38. 8.7.1 CymaBay Therapeutics Inc Company Information
  39. 8.7.2 CymaBay Therapeutics Inc Business Overview
  40. 8.7.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  42. 8.7.5 CymaBay Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Homozygous Familial Hypercholesterolemia Treatment Value Chain Analysis
  2. 9.1.1 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process
  6. 9.2 Homozygous Familial Hypercholesterolemia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
  9. 9.2.3 Homozygous Familial Hypercholesterolemia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst